溶血磷脂酸受体在乳腺癌中的表达及其意义

Expression of lysophosphatidic acid receptors in breast cancer and their significances

目的探讨溶血磷脂酸受体（LPAR）在乳腺癌中的表达及其与乳腺癌患者临床病理特征的关系。方法采用实时定量聚合酶链反应（qRT-PCR）法和免疫组织化学法分别测定LPARl、LPAR2、LPAR3的mRNA和蛋白在82例乳腺癌组织、55例乳腺腺瘤组织及37例癌旁正常乳腺组织中的表达，分析LPAR在乳腺癌中的表达与患者临床病理特征的相关性。结果乳腺癌组织中LPAR2和LPAR3mRNA及蛋白的表达水平均高于癌旁正常组织及乳腺腺瘤组织（均P〈0．05）。三组问LPARlmRNA的表达水平差异无统计学意义（X^2=1．908，P〉0．05）。乳腺癌患者LPARlmRNA的表达水平与临床病理特征无相关性（P〉0．05）；LPAR2在绝经后患者中的表达水平高于绝经前患者（X^2=4．821，P〈0．05），与其他临床病理因素无关（P〉0．05）；LPAR3的高表达与淋巴结转移及雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体2（HER2）的缺乏有相关性（均P〈0．05）。结论LPAR在乳腺癌中呈差异性表达，其过表达与患者绝经、淋巴结转移及ER、PR、HER2状况相关。

Objective To evaluate the differential expression of lysophosphatidic acid receptor （LPAR） in breast cancer （BC）, and its relationship with clinicopathological features of BC patients. Methods The qRT-PCR and immunohistochemical staining were used to detect the LPAR expression in 37 normal tissues, 55 benign disease tissues and 82 BC tissues, besides, the correlation of LPAR expression with clinicopathological data was also analyzed. Results The expression levels of LPAR2 and LPAR3 mRNA and protein in BC tissues were higher than those in normal benign tissues （all P〈 0.05）. LPAR1 mRNA expression had no difference in three tissues （X^2 = 1.908, P 〉0.05）. LPAR1 expression was not associated with clinicopathological features in BC tissues （P 〉 0.05）. LPAR2 expression in postmenopausal patients was higher than that in premenopausal patients （X^2 = 4.821, P〈 0.05）. LPAR3 expression was significantly associated with nodal metastasis, estrogen receptor （ER）, progesterone receptor （PR） and human epidermal growth factor receptor 2 （HER2） in BC tissues （all P 〈 0.05）. Conclusion LPAR in BC tissues has differential expression, which is associated with nodal metastasis, ER, PR and HER2.